None listed
Conditions
Interventions
Others(split-face) : 1. After cleansing, dry the skin.
2. Apply Part 1 oil serum containing Crystal Hyaluronic Acid and gen
tly rub for 20–30 seconds (the control group followed the same proce
dure).
Sponsors
mariedm
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Healthy female or male volunteers aged 19 to 60 yrs., with dry facial skin (skin moisture content of 49 A.U. or below), visible wrinkles on the crow’s feet, enlarged pores (pore grade 3 or higher) and hyperpigmentation (blemishes) 2. Those who have a lack of skin elasticity 3. Those to whom the purpose and contents of the test and possible adverse reactions were explained in detail by the investigator and willingly signed the informed consent form 4. Those who are able to do a follow-up observation during the testing period
Exclusion criteria
Exclusion criteria: 1. Individuals who are pregnant, breastfeeding, or planning to become pregnant within the next 6 months. 2. Individuals who do not wish to participate or who have not provided written informed consent. 3. Individuals with psychiatric disorders, intellectual disabilities, or infectious skin diseases. 4. Individuals with chronic wasting diseases (e.g., asthma, diabetes, hypertension, hyperthyroidism or hypothyroidism). 5. Individuals with skin abnormalities in the test area, such as moles, tattoos, erythema, telangiectasia, or scars. 6. Individuals with a history of severe sensitivity or allergic reactions to cosmetics, pharmaceuticals, or sun exposure. 7. Individuals with skin conditions in the test area, including dermatological diseases, allergies, sensitive or reactive skin, or atopic dermatitis. 8. Individuals who have been using topical agents containing antibiotics, immunosuppressants, steroids, or treatments for chronic skin diseases on the test area for more than 1 month. 9. Individuals who have used cosmetics or pharmaceuticals with similar or related efficacy on the test area within 3 months prior to study initiation. 10. Individuals currently taking antihistamines or anti-inflammatory drugs. 11. Individuals who have participated in a similar clinical study within the past 3 months. 12. Individuals who have received or plan to receive dermatological procedures (e.g., laser treatment, hair removal, or other skin treatments) on the test area within 3 months prior to study initiation. 13. Employees of the research institute. 14. Any other individuals deemed unsuitable for participation by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in skin barrier function compared to the control product;Improvement in skin hydration compared to the control product;Improvement in periorbital wrinkle appearance compared to the control product;Improvement in skin density compared to the control product;Improvement in pore parameters (number and area measured by instrumental analysis) compared to the control product;Improvement in skin pigmentation (dark spots) compared to the control product;Improvement in skin elasticity compared to the control product | — |
Secondary
| Measure | Time frame |
|---|---|
| Skin adverse reactions | — |
Countries
Korea, Republic of
Contacts
Public ContactPark yuri
mariedm
Outcome results
None listed